Ultramicronized palmitoylethanolamide (Um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): Retrospective observational study on 407 patients

Autor: Paola Bellamoli, Giovanna Del Balzo, Enrico Polati, Carlo Schievano, Piercarlo Sarzi-Puttini, Massimo Parolini, Alvise Martini, Vittorio Schweiger, Katia Donadello
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Adult
Male
medicine.medical_specialty
Fibromyalgia Impact Questionnaire (FIQ)
Symptoms Severity Score (SSS)
Visual Analogue Scale (VAS)
Widespread Pain Index (WPI)
adverse events (AEs)
fibromyalgia syndrome (FMS)
mast-cells (MC)
ultramicronized palmitoylethanolamide (um-PEA)
Constipation
Fibromyalgia
Population
Palmitic Acids
03 medical and health sciences
0302 clinical medicine
Bloating
Quality of life
Internal medicine
medicine
Humans
Adverse effect
education
Pain Measurement
Retrospective Studies
Pharmacology
education.field_of_study
business.industry
General Neuroscience
Retrospective cohort study
Middle Aged
medicine.disease
Amides
Settore MED/16 - Reumatologia
030104 developmental biology
Treatment Outcome
Italy
Ethanolamines
Vomiting
Quality of Life
Female
medicine.symptom
business
030217 neurology & neurosurgery
Popis: Background: Fibromyalgia syndrome is a chronic multifaceted disease characterized by widespread pain, muscle stiffness, fatigue, unrefreshing sleep and cognitive disorders. To date, no medication has been shown to significantly improve pain, associated symptoms and Quality of Life in fibromyalgic patients. Methods: In this retrospective observational study, we analyzed data regarding 407 patients with diagnosis of fibromyalgia syndrome who between 2013 and 2016 have been prescribed orally ultramicronized palmitoylethanolamide tablets (Normast® Epitech Group SpA, Saccolongo, Italy) regardless of the concomitant pharmacological therapy (add-on treatment). Results: Regarding efficacy, in the 359 analyzed patients, the change over time in Visual Analogue Scale pain score was statistically significant, ranging from 75.84 (±15.15) to 52.49 (±16.73) (p Conclusion: The results of ultramicronized palmitoylethanolamide treatment in this retrospective analysis represent an important step for the development of a new and well-tolerated therapy for fibromyalgia syndrome, mostly suitable for these patients who need long-term treatments. Further methodologically stronger studies will be necessary to validate our observation.
Databáze: OpenAIRE
Externí odkaz: